138499-16-8

Usage

Uses

Used in Organic Synthesis:
2-(t-Butyldiphenylsilanyloxy)Ethanol is used as a reagent for the protection and deprotection of hydroxyl groups in organic molecules, which is crucial for controlling the reactivity of these groups during complex organic reactions.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 2-(t-Butyldiphenylsilanyloxy)Ethanol is utilized as a versatile building block in the synthesis of various organic compounds, contributing to the development of new drugs and medicinal agents.
Used in Agrochemical Production:
Similarly, in agrochemicals, 2-(t-Butyldiphenylsilanyloxy)Ethanol serves as a key intermediate in the synthesis of bioactive molecules, enhancing the effectiveness of agricultural products.
Used in Materials Science:
2-(t-Butyldiphenylsilanyloxy)Ethanol is also employed in materials science for the synthesis of advanced materials, leveraging its structural properties to create novel compounds with specific applications.
Used as a Precursor in Silicone-based Materials:
Due to the presence of the silicon atom in its structure, 2-(t-Butyldiphenylsilanyloxy)Ethanol can act as a precursor in the synthesis of various silicone-based materials, broadening its applications in industries that rely on such materials for their products.

Upstream product

• 107-21-1 ethylene glycol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 130372-07-5 4-(tret-butyldiphenylsilyloxy)butan-1-ol 
• 10310-21-1 2-Amino-6-chloropurin 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 136787-49-0 3-(tert-butyldiphenylsilyloxy)prop-1-ene 
• 288-32-4 1H-imidazole 

Downstream Products

• 184691-03-0 (E)-(2R,3S)-1-(tert-Butyl-diphenyl-silanyloxy)-3-methoxymethoxy-hex-4-en-2-ol 
• 184691-04-1 C₃₀H₄₈O₄Si₂ 
• 184691-05-2 (2R,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-4-(tert-butyl-diphenyl-silanyloxy)-2-methoxymethoxy-butyraldehyde 
• 184690-99-1 (E)-(2R,3S)-6-(tert-Butyl-dimethyl-silanyloxy)-1-(tert-butyl-diphenyl-silanyloxy)-3-methoxymethoxy-hex-4-en-2-ol 
• 184691-00-7 (E,4S,5R)-1,5-(bis(tert-butyldimethylsilyl)oxy)-6-[(tert-butyldiphenylsilyl)oxy]-4-(methoxymethoxy)-4-hexene 
• 184691-01-8 (2R,3S,4S,5R)-1,5-Bis-(tert-butyl-dimethyl-silanyloxy)-6-(tert-butyl-diphenyl-silanyloxy)-4-methoxymethoxy-hexane-2,3-diol 
• 184691-06-3 (E)-(2R,3S,4R,5R)-2,5-Bis-(tert-butyl-dimethyl-silanyloxy)-1-(tert-butyl-diphenyl-silanyloxy)-3-methoxymethoxy-oct-6-en-4-ol 
• 184691-07-4 C₄₄H₈₀O₆Si₄ 
• 136022-54-3 1-(tert-butyldiphenylsiloxy)-3-methyl-2-butanone 
• 139167-05-8 1-(tert-butyldiphenylsiloxy)-3-methyl-2-butanol 
• 139167-20-7 1-(tert-butyldiphenylsiloxy)-2-cyclopropylidene-3-methylbutane 
• 139167-11-6 1-(tert-butyldiphenylsiloxy)-4-methyl-2-pentanone 
• 139167-10-5 1-(tert-butyldiphenylsiloxy)-2-hexanone 
• 139167-07-0 1-(tert-butyldiphenylsiloxy)-4-methyl-2-pentanol 

Relevant academic research and scientific papers

Alkyne Aminopalladation/Heck and Suzuki Cascades: An Approach to Tetrasubstituted Enamines

Alkyne aminopalladation reactions starting from tosylamides are reported. The emerging vinylic Pd species are converted either in an intramolecular Heck reaction with olefinic units or in an intermolecular Suzuki reaction by using boronic acids exhibiting broad functional group tolerance. Tetra(hetero)substituted tosylated enamines are obtained in a simple one-pot process.

Ambruticins: tetrahydropyran ring formation and total synthesis

The ambruticins are a family of polyketide natural products which exhibit potent antifungal activity. Gene knockout experiments are in accord with the proposal that the tetrahydropyran ring of the ambruticins is formedviathe AmbJ catalysed epoxidation of the unsaturated 3,5-dihydroxy acid, ambruticin J, followed by regioselective cyclisation to ambruticin F. Herein, a convergent approach to the total synthesis of ambruticin J is described as well as model studies involving epoxidation and cyclisations of unsaturated hydroxy esters to give tetrahydropyrans and tetrahydrofurans. The total synthesis involves preparation of three key fragments which were unitedviaa Suzuki-Miyaura cross-coupling and Julia-Kocienski olefination to generate the required carbon framework. Global deprotection to a triol and selective oxidation of the primary alcohol gave, after hydrolysis of the lactone, ambruticin J.

Scaling Amatoxin Synthesis with an Improved Route to (2 S,3 R,4 R)-Dihydroxyisoleucine Exemplified by a Toxic, Clickable α-Amanitin Analogue

Here we report a scalable synthesis of the key amino acid residue, (2S,3R,4R)-4,5-dihydroxyisoleucine (DHIle) in α-amanitin, that in turn enables the scalable synthesis of an equipotent analogue, Asn(N-ethylazide)-S,6′-dideoxy-α-amanitin, suitable for CuAAC conjugation to empower studies on therapeutic antibody-drug conjugates.

Total Synthesis of Citreochlorol Monochloro Analogues via a Catalytically Enantioselective Carbonyl Allylation

An efficient synthetic route to citreochlorol analogues, halogenated polyketide secondary metabolites, is described. The key features are Krische s enantioselective carbonyl allylation, IBr-promoted cyclization, and regioselective epoxide opening. The importance of the route lies in accessing a versatile epoxy ether that enables the formation of citreochlorol monochloro derivatives.

NOVEL CARBONATE ANALOGUES BEARING PTEROSTILBENE AMINO ACIDS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS

A series of novel analogs of water soluble pterostilbene amino acid bearing carbonates were synthesized, which show activities in treating a non-alcoholic fatty liver disease and a nonalcoholic steatohepatitis (NASH).

Total Synthesis of Phospholipomannan of Candida albicans

First, total synthesis of the cell surface phospholipomannan anchor [β-Manp-(1 → 2)-β-Manp]n-(1 → 2)-β-Manp-(1 → 2)-α-Manp-1 → P-(O → 6)-α-Manp-(1 → 2)-Inositol-1-P-(O → 1)-phytoceramide of Candida albicans is reported. The target phospholipomannan (PLM) anchor poses synthetic challenges such as the unusual kinetically controlled (1 → 2)-β-oligomannan domain, anomeric phosphodiester, and unique phytoceramide lipid tail linked to the glycan through a phosphate group. The synthesis of PLM anchor was accomplished using a convergent block synthetic approach using three main appropriately protected building blocks: (1 → 2)-β-tetramannan repeats, pseudodisaccharide, and phytoceramide-1-H-phosphonate. The most challenging (1 → 2)-β-tetramannan domain was synthesized in one pot using the preactivation method. The phytoceramide-1-H-phosphonate was synthesized through an enantioselective A3 three-component coupling reaction. Finally, the phytoceramide-1-H-phosphonate moiety was coupled with pseudodisaccharide followed by deacetylation to produce the acceptor, which on subsequent coupling with tetramannosyl-H-phosphonate provided the fully protected PLM anchor. Final deprotection was successfully achieved by Pearlman's hydrogenation.

TRANSGLUTAMINASE 2 (TG2) INHIBITORS

Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.

METHODS OF SYNTHESIZING LABELED NUCLEOSIDES

Disclosed herein, inter alia, are compounds, compositions, and methods of synthesizing labeled nucleosides.

THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION

Disclosed are a compound and a pharmaceutical composition that exhibit an excellent drug efficacy against a tumor, in particular a tumor which has acquired resistance to gemcitabine. Specifically, provided is a thionucleoside derivative represented by General Formula [1] (in the formula, R1 represents a hydroxyl group which may be protected, a C1-20 alkoxy group which may be substituted, or the like; R2 represents a C1-20 alkoxy group which may be substituted, a C3-8 cycloalkoxy group which may be substituted, or the like; and R3 represents a hydrogen atom or the like); or a salt thereof. Further, provided is a pharmaceutical composition containing such a thionucleoside derivative or a salt thereof.

A Sequential Homologation of Alkynes and Aldehydes for Chain Elongation with Optional 13C-Labeling

Terminal alkynes (RCCH) are homologated by a sequence of ruthenium-catalyzed anti-Markovnikov hydration of alkyne to aldehyde (RCH2CHO), followed by Bestmann-Ohira alkynylation of aldehyde to chain-elongated alkyne (RCH2CCH). Inverting the sequence by starting from aldehyde brings about the reciprocal homologation of aldehydes instead. The use of 13C-labeled Bestmann-Ohira reagent (dimethyl ((1-13C)-1-diazo-2-oxopropyl)phosphonate) for alkynylation provides straightforward access to singly or, through additional homologation, multiply 13C-labeled alkynes. The labeled alkynes serve as synthetic platform for accessing a multitude of specifically 13C-labeled products. Terminal alkynes with one or two 13C-labels in the alkyne unit have been submitted to alkyne-azide click reactions; the copper-catalyzed version (CuAAC) was found to display a regioselectivity of >50 000:1 for the 1,4- over the 1,5-triazine isomer, as shown analytically by 13C NMR spectroscopy.